Navigation Links
NeuroSigma Subsidiary Acquires Thin-Film Nitinol Fabrication Patent Portfolio
Date:5/16/2012

LOS ANGELES, May 16, 2012 /PRNewswire/ -- NeuroSigma, Inc., a Los Angeles-based medical device company, today announced that its majority-owned subsidiary, NSVascular, Inc. (NSV), acquired a portfolio of patents and related trade secrets covering the fabrication of Thin-Film Nitinol (TFN) from TiNi Alloy Company, including U.S. Patent No. 6,746,890 entitled "Three Dimensional Thin Film Devices and Methods of Fabrication," an important piece of the portfolio covering the production of three-dimensional TFN constructs.

NSV was formed in 2011 to commercialize TFN-covered stent technology, exclusively licensed from the University of California, Los Angeles (UCLA).  Nitinol is a superelastic nickel and titanium alloy with unique properties that allow deformation and subsequent recovery of the full shape upon exposure to body heat. NSV is initially focused on developing and commercializing TFN-covered stents for endovascular applications, with its most advanced product being a flow-diverting stent for treating intracranial aneurysms.  The unique properties of TFN allow for the fabrication of stents that can be compressed and inserted into vessels through very small catheters, a necessity for endovascular technologies being used in the brain.

Intracranial aneurysms result from weaknesses in cerebral blood vessels, which can rupture; potentially leading to stroke and death. It is estimated that up to one in fifteen Americans will develop an intracranial aneurysm in their lifetime. Current endovascular techniques for treating this condition include placing small coils inside the aneurysm sac. While the procedure is effective, it can be time-consuming and the aneurysms are prone to recurrence.

In contrast, flow-diverting stents may offer a simpler and more permanent solution, whereby a minimally-invasive catheter is used to insert the device into the blood vessel over the neck of the aneurysm, resulting in diversion of blood away from the aneurysm sac. Preclinical data indicates that NSV's TFN-based flow diverter promotes faster occlusion and resorption of the aneurysm, thus lowering the chance of recurrence.

David Johnson, Ph.D., founder, lead inventor and President of TiNi Alloy Co, recently joined NeuroSigma as Director of Advanced Materials to spearhead the flow-diverter development program. "I am pleased to transfer these important assets from TiNi Alloy to NSV," said Dr. Johnson. "The technology covered in this portfolio provides key fabrication advantages as we forge ahead with our next generation flow-diverter."

"TiNi Alloy's comprehensive patent portfolio and related trade secrets are very complementary to the TFN-covered stent intellectual property NSV exclusively licensed from UCLA last year," said Leon Ekchian, Ph.D., President and CEO of NeuroSigma. Colin Kealey, M.D., Manager of Business Development at NeuroSigma added, "Flow-diverting stents are one of the highest potential growth areas in the neurovascular market, and we believe that our TFN-based flow-diverter offers significant advantages over existing technologies."

CAUTION: NSV's TFN covered stents are investigational devices and are limited by Federal (or United States) law to investigational use.

About NeuroSigma Inc.NeuroSigma is a Los Angeles-based medical technology company established to develop early stage technologies with the potential to transform medical practice. Currently, NeuroSigma is focused on a number of neuromodulation therapies and through its majority-owned subsidiary, NSVascular, Inc. on Thin-Film Nitinol covered stents for endovascular applications. NeuroSigma employs two neuromodulation therapy platforms: Trigeminal Nerve Stimulation (TNS) and Deep Brain Stimulation (DBS). NeuroSigma has amassed significant intellectual property licensed on an exclusive basis from the University of California, Los Angeles (UCLA), including potential therapies for epilepsy, depression, post-traumatic stress disorder (PTSD) and attention-deficit hyperactivity disorder (ADHD) via TNS, and for PTSD, obesity and cachexia via DBS. For more information about NeuroSigma, please visit http://www.neurosigma.comNeuroSigma Contacts: Dr. Leon Ekchian, President & CEOTel: 310-479-3100Email:
lekchian@neurosigma.comNeuroSigma, Inc.Website:  http://www.neurosigma.com Mr. Mark Collinson, PartnerTel: +1-310-954-1343Email:  mark.collinson@ccgir.com CCG Investor Relations


'/>"/>

SOURCE NeuroSigma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroSigma, Inc. Retains CCG Investor Relations
2. NSVascular, Inc., a NeuroSigma Subsidiary, Signs an Exclusive License Covering UCLAs Thin-Film Nitinol (TFN) Stent Technology for Endovascular Applications
3. NeuroSigma Responds to Substantial Interest Generated by NPR Story on Promising Epilepsy Clinical Trial
4. NeuroSigma Receives Notice of Award from NIH for an STTR Grant for its Trigeminal Nerve Stimulation Therapy for Epilepsy
5. NeuroSigma Funds First-Ever Pediatric Clinical Trial to Study Non-Invasive External Trigeminal Nerve Stimulation for the Treatment of ADHD
6. NeuroSigma to Exhibit at the 2011 American Epilepsy Society Annual Meeting and Introduce External Trigeminal Nerve Stimulation - the USB Port to the Brain™
7. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
8. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
9. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
10. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
11. New Places and People - Truphatek opens USA subsidiary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2020)... ... May 24, 2020 , ... May is National Electrical Safety ... public to know what safety resources are available. Every year during National ... education campaign to inform the public about safety steps that can reduce the ...
(Date:5/21/2020)... ... May 21, 2020 , ... The COVID-19 outbreak has changed the ... year, leadership at SPIRE Institute & Academy (IA) have closely followed the recommendations of ... DeWine’s office to prevent the spread of coronavirus, and keep students, campers, parents, guests ...
(Date:5/21/2020)... CHICAGO (PRWEB) , ... May 21, 2020 , ... Cataract ... of all cases of blindness in all nations. In the United States, more than ... of Vision: Forecasting the Prevalence and Costs of Vision Problems .” As the population ...
Breaking Medicine Technology:
(Date:5/21/2020)... ... May 21, 2020 , ... Having ... of GSCG, VITA NOVAS has already gained ground with the inherited reputation of ... stimulating biological products intravenously, guaranteeing an effective way for the ingredients to become ...
(Date:5/21/2020)... KENNESAW, Ga. (PRWEB) , ... May 21, 2020 , ... ... Representatives District 35, has been endorsed by Planned Parenthood Southeast Advocates (PPSEA). ... candidates who support family planning and the full range of reproductive health care. PPSEA ...
(Date:5/21/2020)... ... May 21, 2020 , ... ESO , the leading data ... the findings of its 2020 ESO Fire Service Index . The Index looks ... fire-related calls, first apparatus turnout time and travel time, the most common property types ...
(Date:5/21/2020)... ... 2020 , ... Casenet® LLC today released TruCare 2020, an ... and utilization management at health insurance plans. Developed over two years with input ... and automation upgrades to all of its existing features, introduces more system-to-system integration, ...
(Date:5/21/2020)... Wis. (PRWEB) , ... May 21, 2020 , ... ... Term care industry announced the release of the SafeHealth screening software. This ... without the need for additional staff or the cost of additional paperwork management. , ...
Breaking Medicine News(10 mins):